IP Library Granted Patent US 10,696,745
Granted Patent B2
US 10,696,745 · App. 15/580,281 · Granted Jun 30, 2020

Anti-PD-L1 antibodies

Inventors: Yong Zheng (Shanghai, CN); Jing Li (Lexington, MA); Zhisheng Chen (Shanghai, CN)
C07K16/2827G01N33/566C07K2317/24C07K2317/565C07K2317/74C07K2317/76C07K2317/92G01N2333/70596G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,696,745
App. No.
15/580,281
Granted
Jun 30, 2020
Kind
B2
Abstract

The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

Claims (16)

1. An isolated monoclonal antibody or an antigen binding fragment thereof, comprising a heavy chain variable region comprising: SEQ ID NOs: 1, 2, and 3, and a light chain variable region comprising: SEQ ID NOs: 4, 5 and 6, wherein the monoclonal antibody or an antigen binding fragment thereof specifically binds to human or monkey PD-L1.

2. The antibody or an antigen binding fragment thereof of claim 1 , comprising:

a) a heavy chain variable region comprising SEQ ID NO: 7; and a light chain variable region comprising SEQ ID NO: 9;

b) a heavy chain variable region comprising SEQ ID NO: 11; and a light chain variable region comprising SEQ ID NO: 13;

c) a heavy chain variable region comprising SEQ ID NO: 11; and a light chain variable region comprising SEQ ID NO: 16;

d) a heavy chain variable region comprising SEQ ID NO: 18; and a light chain variable region comprising SEQ ID NO: 13; or

e) a heavy chain variable region comprising SEQ ID NO: 18; and a light chain variable region comprising SEQ ID NO:22.

3. The antibody or antigen-binding fragment thereof of claim 1 , which is a diabody, a scFv, an scFv dimer, a BsFv, a dsFv, a (dsFv) 2 , a dsFv-dsFv′, an Fv fragment, a Fab, a Fab′, a F(ab′) 2 , or a ds diabody.

4. The antibody or antigen-binding fragment thereof of claim 1 , further comprising a conjugate.

5. An isolated polynucleotide encoding the antibody or an antigen binding fragment thereof of claim 1 .

6. A vector comprising the isolated polynucleotide of claim 5 .

7. A host cell comprising the vector of claim 6 .

8. A method of expressing the antibody or antigen-binding fragment thereof of claim 1 , comprising culturing the host cell comprising a vector comprising an isolated polynucleotide encoding the antibody or an antigen binding fragment thereof of claim 1 , under the condition at which the polynucleotide is expressed.

9. A kit comprising the antibody or antigen-binding fragment thereof of claim 1 .

10. A method of detecting presence or level of human or monkey PD-L1 in a biological sample, comprising exposing the biological sample to the antibody or antigen-binding fragment thereof of claim 1 , and determining the presence or level of human or monkey PD-L1 in the sample.

11. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 and one or more pharmaceutically acceptable carriers.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2017
From: ZHENG, YONG; LI, JING; CHEN, ZHISHENG
To: WUXI BIOLOGICS (SHANGHAI) CO. LTD.
Reel/Frame 044325/0024 →
Continuity (1)
Related Publication 20180162944A1 · Jun 14, 2018